Advertise on podcast: Beyond the Endpoint

Hosts Manesh Patel and Emily O'Brien look past the headlines on Novartis' Lp(a) drug trial results, AI agents in medicine, the FDA's Operation Trailblazer to speed up clinical trials, Dolly Parton's support for COVID research, and the case for steady NIH funding. https://dcri.org/blog/s3-ep-3-beyond-headlines

To mark DCRI's 30th anniversary, this first episode in a two-part series features founding director Robert Califf and current Executive Director Adrian Hernandez as they look back at the institute's evolution and ahead to its future. Part two arrives Sept. 23. https://dcri.org/blog/s3-ep-1-foundation-future-30-years-califf-hernandez

In this Beyond the Headlines episode, we examine the FDA's push for real-time clinical trial data, an executive order making psychedelic research a federal priority, advances in CAR T-cell therapy for autoimmune conditions, and viral claims about antihistamines as a treatment for premenstrual dysphoric disorder. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-16-beyond-headlines

COPD is the third leading cause of death worldwide. Yet the disease remains underdiagnosed and underfunded. Host Emily O'Brien and pulmonologist Chris Mosher discuss stigma, funding disparities, barriers to care, and promising research that's bringing new hope to patients. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-15-copd-gap-diagnosis-treatment-and-access

Why is it so hard to change our behavior, even when we know what we should be doing? Host Emily O'Brien sits down with urologist and DCRI faculty member Dr. Chuck Scales to discuss the science of behavior change and surprising findings from the PUSH trial, the largest kidney stone prevention trial to date. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-14-hard-habits-what-kidney-stones-teach-us-about-behavior-change

During a cardiac event, every minute without CPR reduces survival chances by 10%. In this episode, DCRI's Tyler Cope discusses a coordinated effort to train nearly 20,000 people across North Carolina in a single day and what it takes to get more bystanders to take action in an emergency. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-13-closing-gap-cardiac-arrest-survival-why-bystanders-matter

Nearly 40% of Americans have experienced back pain in the past three months, yet treatment hasn't kept pace with the science. Host Emily O'Brien talks with DCRI researcher Steven George about biopsychosocial models of care, pragmatic trials, and building a better system for chronic pain management. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-12-research-relief-raising-standard-back-pain-treatment

Double-board-certified pediatrician and allergist/immunologist Zach Rubin joins Manesh Patel for an evidence-based discussion on allergy science. The conversation dives into the differences between allergies and sensitivities, recent shifts in food allergy prevention, environmental and metal allergies, and FDA-approved treatments, including Xolair and needle-free EpiPens. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-11-all-about-allergies-evolution-care-evidence-dr-zach-rubin

Guests Michael Pencina and Suresh Balu join the Beyond the Endpoint hosts to explore the impact of AI in healthcare. They discuss the role of AI-powered tools in research, clinical care, and operations, while examining evidence standards, transparency challenges, and the potential evolution of the physician-patient relationship. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-10-innovation-implementation-ai-action

Kick off 2026 with hosts Manesh Patel and Emily O'Brien as they evaluate last year's most discussed health stories and wellness trends, cannabis reclassification, and a shingles vaccine-dementia study. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-9-beyond-headlines

Hosts Manesh Patel and Emily O'Brien share their amusing and inspiring personal and professional trajectories, exploring how mentors shaped their paths in clinical research, why asking unconventional questions matters, and how success rarely follows a straight line. 🎙️ Listen now for the full conversation: https://dcri.org/blog/s2-ep-8-behind-voices-get-know-emily-manesh

Hosts Emily O’Brien and Manesh Patel sit down with Dr. Ajay Kohli and Dr. Julius Wilder for a dual-perspective conversation on colorectal cancer, where they discuss personal experiences, the importance of early detection, screening disparities, and how equitable access to care saves lives. 🔗Access resources related to this episode: https://dcri.org/blog/s2-ep-7-provider-patient-dual-perspective-colorectal-cancer

Recorded at the 2025 American Heart Association Scientific Sessions, hosts Manesh Patel and Emily O'Brien discuss late-breaking cardiovascular research, including gene-editing therapy for cholesterol, AFib management strategies, and, for coffee lovers, the DECAF trial's findings on caffeine and heart rhythm. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-6-beyond-headlines #AHA25 #beyondtheendpoint #cardiology #podcast #hearthealth #clinicalresearch

Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-5-connecting-dots-broader-applications-glp-1s-and-where-were-headed-next

In this second episode of our obesity series, preventive cardiologist Neha Pagidipati sheds light on the discovery, impact, and uses of GLP-1s, like Ozempic and Mounjaro. Learn about the impact these medications are having on diabetes, heart disease, and weight management. 🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-4-obesity-glp-1s-and-evidence-what-data-tells-us